Revelstoke Capital Partners Recapitalizes AOM Infusion

April 15, 2025

Revelstoke Capital Partners completed a recapitalization of AOM Infusion, a specialty infusion provider that delivers IVIG, biologics and other therapies for chronic conditions. Revelstoke will support AOM's management team to expand therapeutic focus areas, deepen clinical expertise and grow the company's patient reach; terms were not disclosed.

Buyers
Revelstoke Capital Partners
Targets
AOM Infusion
Location
Texas, United States
Transaction Type
Recapitalization

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.